{
  "asset": {
    "name": "TransCon CNP",
    "company": "Ascendis Pharma",
    "ticker": "ASND",
    "target": "C-type natriuretic peptide pathway",
    "mechanism": "CNP therapy that releases the FGFR3-induced brake, enabling complementary effect of growth hormone",
    "modality": "TransCon prodrug technology",
    "partner": null
  },
  "clinical_development": {
    "current_stage": "Phase 3",
    "indications_in_development": [
      "Achondroplasia",
      "Hypochondroplasia"
    ]
  },
  "trials": [],
  "investment_thesis": [
    "Combination therapy exceeds historical benchmarks for growth with tripling of efficacy compared to TransCon CNP monotherapy",
    "Well-positioned to be the leader in growth disorders with once-weekly TransCon CNP and TransCon hGH",
    "Complementary mechanisms: TransCon CNP releases the brake enabling GH to accelerate outcomes"
  ],
  "key_risks": [],
  "upcoming_catalysts": [],
  "_source_pages": [
    3,
    5,
    17
  ],
  "_last_extracted": "2026-02-04T13:31:56.899521"
}